source
- Eli Lilly announces second partnership this year to advance recombinase-based gene editingEli Lilly has entered a second partnership this year aimed at developing recombinase-based gene‑editing technologies. The collaboration follows earlier efforts to explore enzymes that can precisely…
- Rocket Pharmaceuticals sells pediatric disease priority review voucher for $180 million; Oruka eyes $500 million offeringRocket Pharmaceuticals, a New Jersey gene-therapy company, sold its priority review voucher for a rare pediatric disease to an undisclosed buyer for $180 million. The voucher was earned after the…